Modafinil is a wakefulness-promoting agent which has been used for the treatment of sleeping disorder like narcolepsy, sleep apnea and excessive sleeping disorder since 1998. Modafinil was first developed in France during an experiment of series of benzhydryl sulfinyl compounds including Adrafinil.
Modafinil is considered a smart drug which helps improves cognition. It helps individuals who are suffering from the sleeping disorder but apart from that Modafinil has been used for many other purposes. In 1998 Modafinil was first approved by The US FDA for the treatment of narcolepsy and later in 2003 for sleep apnea and excessive daytime sleeping.
But every since Modafinil has been introduced to the pharmaceutical industry it has been a big question about its addictive and liability status. Modafinil is use for patients who are suffering from sleeping disorder but because of its other qualities, it has been off-label prescribed for fatigue. Some for reputed scientist have suggested that healthy responsible adults should be allowed to use smart drugs like Modafinil to boost their intellectual creativity.
Nora D Follow the MD of National Institute on Drug Abuse has reported during her research that Provigil might be addictive then it is considered. The use of this medication has been increased since people have promoted the off-label uses of Modafinil as a cognitive enhancer.
Volkow has stated to Web MD that if this drug is not used with proper medical oversight it could lead to addiction as it has side effects. There was an experiment carried out involving ten healthy men who agree to take two sets of PET scans after taking Provigil or either an inactive placebo pill. Later on, the scans showed that Modafinil obstructs dopamine transporters from communicating. This is why Modafinil is considered as a risk to addiction as the increase of dopamine in the brain shows alertness and vigilance. This quality of Modafinil is compared to that of cocaine and methamphetamine as this drug triggers the same mechanism, but much faster compared to Modafinil.
Volkaw notes that Modafinil has no effects on mice lacking dopamine transporters. This indicated that its dopamine-enhancing effect is vital. Whereas, Professor David Weinshenker of Emory University, Atlanta has performed some of the experiments on the Volkow mice studies and Weinshenker agree that Modafinil shares one brain receptor with cocaine, but doesn’t emphasize on the drug addiction potential.
He asks “what is Modafinil street value”
There are no addicts buying or selling Modafinil around. He stated that most people who take Modafinil have not experienced ecstasy or being high in terms of addiction and dependence, it just doesn’t do that. Weinshenker notes that because of Modafinil quality and conditional safety it is possible to explore it for a wide number of disorder like ADHD, autism, and depression. As Modafinil offers a major benefit over other stimulant promoting wakefulness with the sleep rebound it is not considered as an addictive drug.
He says the drug offers a major benefit over amphetamine-like stimulants in that it promotes wakefulness without the sleep rebound a need for extra sleep when the drug wears off.
That being said it is safer to say that Modafinil Addiction status liability is Very low. It is found out that the Dependence liability of Modafinil Psychologically of a person on Modafinil is Very low and Physically it is Negligible.